[ad_1]
Times Square Capital Management, an equity investment management company, has released its fourth quarter “U.S. Small Cap Growth Strategy” letter to investors. You can download a copy of the same here. The fund returned 9.15% (net) for the quarter, compared to the Russell 2000 Growth Index’s return of 12.75%. For the year, the fund returned 15.96% (net), while the index returned 18.66%. Plus, check out the fund’s top 5 holdings to find out the best stocks for 2023.
Times Square Capital’s U.S. Small Cap Growth Strategy featured stocks such as RAPT Therapeutics, Inc. (NASDAQ:RAPT) in its Q4 2023 investor letter. RAPT Therapeutics, Inc. (NASDAQ:RAPT), headquartered in South San Francisco, California, is a clinical-stage immunology-based biopharmaceutical company. On March 21, 2024, RAPT Therapeutics, Inc. (NASDAQ:RAPT) stock closed at $8.51 per share. His 1-month return for RAPT Therapeutics, Inc. (NASDAQ:RAPT) is -2.41%, and the company’s stock has lost 51.23% of its value over the past 52 weeks. RAPT Therapeutics, Inc. (NASDAQ:RAPT) has a market capitalization of $296,128,000.
TimesSquare Capital US Small Cap Growth Strategy says this about RAPT Therapeutics, Inc. (NASDAQ:RAPT) in its Q4 2023 investor letter:
“We also RAPT Therapeutics Co., Ltd. (NASDAQ:RAPT) is a development biotechnology company focused on inflammation and immunotherapy. The main treatment for RAPT, zernesilnone, is in late-stage clinical trials to address moderate to severe atopic dermatitis (eczema) with a differentiated oral treatment compared to current injectable therapies. Results from the current trial are expected to be available in mid-2024, and early signs are promising. Since the initial purchase, RAPT stock rose 51% during the remainder of the quarter. ”
Scientists in cutting-edge laboratories working with biopharmaceutical compounds.
RAPT Therapeutics, Inc. (NASDAQ:RAPT) isn’t on the list of 30 most popular stocks among hedge funds. Our database shows that RAPT Therapeutics, Inc. (NASDAQ:RAPT) was held by 24 hedge fund portfolios at the end of the fourth quarter, compared to 20 in the prior quarter. Additionally, for investor letters from hedge funds and other leading investors, please visit our Hedge Fund Investor Letters Q4 2023 page.
Recommended articles:
Disclosure: None. This article was originally published on Insider Monkey.
[ad_2]
Source link
